Sage Therapeutics (FRA:SG7) Additional Paid-In Capital : €3,114.31 Mil(As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Additional Paid-In Capital?

Sage Therapeutics's quarterly additional paid-in capital declined from Sep. 2023 (€3,146.20 Mil) to Dec. 2023 (€3,090.65 Mil) but then increased from Dec. 2023 (€3,090.65 Mil) to Mar. 2024 (€3,114.31 Mil).

Sage Therapeutics's annual additional paid-in capital increased from Dec. 2021 (€2,856.31 Mil) to Dec. 2022 (€3,107.05 Mil) but then declined from Dec. 2022 (€3,107.05 Mil) to Dec. 2023 (€3,090.65 Mil).

Sage Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Sage Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Additional Paid-In Capital Chart

Sage Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

2,328.59

2,556.26

2,856.31

3,107.05

3,090.65

Sage Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															3,094.91	3,069.66	3,146.20	3,090.65	3,114.31

Sage Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Sage Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Sage Therapeutics (FRA:SG7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (FRA:SG7) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

SAGE:USA SG7:Germany

Address

215 First Street, Cambridge, MA, USA, 02142

Website

https://www.sagerx.com

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.

Sage Therapeutics (FRA:SG7) Headlines

No Headlines